巴楚医学

参考文献

[1]Lai C C,Shih T P,Ko W C,et al.Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and coronavirus disease-2019(COVID-19):the epidemic and the challenges[J].Int J Antimicrob Agents,2020,55(3):105924.

[2]王春燕,王希营,金红.新型冠状病毒肺炎诊疗方案(试行第七版)[J].兰州大学学报(医学版),2020,46(2):1-7.

[3]Xu X T,Chen P,Wang J F,et al.Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J].Sci China Life Sci,2020,63(3):457-460.

[4]Kim Y J.Letter to the Editor:case of the index patient who caused tertiary transmission of coronavirus disease2019in Korea:the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR[J].J Korean Med Sci,2020,35(7):e88.

[5]Han Q M,Lin Q Q,Jin S H,et al.Coronavirus 2019-nCoV:a brief perspective from the front line[J].J Infect,2020,80(4):373-377.

[6]Cao B,Wang Y M,Wen D N,et al.A trial of lopinavirritonavir in adults hospitalized with severe COVID-19[J].N Engl J Med,2020,382(19):1787-1799.

[7]陈军,凌云,席秀红,等.洛匹那韦利托那韦和阿比多尔用于治疗新型冠状病毒肺炎的有效性研究[J].中华传染病杂志,2020,38(2):86-89.

[8]Brooks M J,Burtseva E I,Ellery P J,et al.Antiviral activity of arbidol,a broad-spectrum drug for use against respiratory viruses,varies according to test conditions[J].Med Virol,2012,84(1):170-181.

[9]Khamitoy R A,Loginova S Y,Shchukina V N,et al.Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures[J].Vopr Virusol,2008,53(4):9-13.

[10]Wang Y,Ding Y,Yang C,et al.Inhibition of the infectivity and inflammatory response of influenza virus by arbidol hydrochloride in vitro and in vivo[J].Biomed Pharmacother,2017,91:393-401.

[11]Xu K J,Chen Y F,Yuan J,et al.Clinical efficacy of Arbidol in patients with 2019novel coronavirus-infected pneumonia:a retrospective cohort study[J].SSRN Electron J,2020.DOI:10.2139/ssrn.3542148.

[12]Li Y P,Xie Z W,Lin W Y,et al.An exploratory randomized,controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19(ELACOI)[J].medRxiv,2020.doi:https://doi.org/10.1101/2020.03.19.20038984.

[13]De Wit E,Feldmann F,Cronin J,et al.Prophylactic and therapeutic remdesivir(GS-5734)treatment in the rhesus macaque model of MERS-CoV infection[J].PNAS,2020,117(12):6771-6776.

[14]Michelle L,Holshue M P H,Chas Debolt M P H,et al.First case of 2019novel coronavirus in the United States[J].N Engl J Med,2020,382(10):929-936.

[15]Wang M,Cao R,Zhang L,et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro[J].Cell Res,2020,30(3):269-271.

[16]Grein J,Ohmagari N,Shin D,et al.Compassionate Use of Remdesivir for Patients with Severe COVID-19[J].N Engl J Med,2020.doi:10.1056/NEJMoa2007016.

[17]Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases'Study of Investigational Antiviral Remdesivir for COVID-19.https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-sciences-statement-on-positive-data-emerging-from-national-instituteof-allergy-and-infectious-diseases-study-of-investigational-antiviral-rem.

[18]Gilead Announces Results From Phase 3Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19.https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-COVID-19.

[19]Wang Y M,Zhang D Y,Du G H,et al.Remdesivir in adults with severe COVID-19:a randomized,doubleblind,placebo-controlled,multicentre trial[J].Lancet,2020.https://doi.org/10.1016/S0140-6736(20)31022-9.

[20]Dyall J,Gross R,Kindrachuk J,et al.Middle east respiratory syndrome and severe acute respiratory syndrome:current therapeutic options and potential targets for novel therapies[J].Drugs,2017,77(18):1935-1966.

[21]Lokugamag K G,Hage A,Schindewolf C,et al.SARSCoV-2is sensitive to type I interferon pretreatment[J].bioRxiv,2020.doi:https://doi.org/10.1101/2020.03.07.982264.

[22]Mona-R L,Blatt L M,Siminovitch K A,et al.Interferon alfacon-1plus corticosteroids in severe acute respiratory syndrome:apreliminary study[J].JAMA,2003,290(24):3222-3228.

[23]Perricone C,Triggianese P,Bartoloni E,et al.The antiviral facet of anti-rheumatic drugs:lessons from COVID-19[J].J Autoimmun,2020.doi:10.1016/j.jaut.2020.102468.

[24]Chen C,Zhang J,Huang J Y,et al.Favipiravir versus arbidol for COVID-19:a randomized clinical trial[J].medRxiv,2020.doi:https://doi.org/10.1101/2020.03.17.20037432.

[25]Cai Q,Yang M,Liu D,et al.Experimental treatment with favipiravir for COVID-19:an open-label control study[J].Engineering,2020.doi:10.1016/j.eng.2020.03.007.

[26]Mccreary E K,Pogue J M.Coronavirus disease 2019treatment:a review of early and emerging options[J].Open Forum Infect Dis,2020,7(4):ofaa105.

[27]Christian M D,Poutanen S M,Loutfy M R,et al.Severe acute respiratory syndrome[J].Clin Infect Dis,2004,38(10):1420-1427.

[28]Omrani A S,Saad M M,Baig K,et al.Ribavirin and interferon alfa-2afor severe Middle East respiratory syndrome coronavirus infection:a retrospective cohort study[J].Lancet Infect Dis,2014,14(11):1090-1095.

[29]Colson P,Rolain J M,Raoult D.Chloroquine for the2019novel coronavirus SARS-CoV-2[J].Int J Antimicrob Agents,2020,55(3):105923.

[30]Yan Y W,Zou Z,Sun Y,et al.Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1virus infection in an animal model[J].Cell Res,2013,23(2):300-302.

[31]Zhai P,Ding Y B,Wu X,et al.The epidemiology,diagnosis and treatment of COVID-19[J].Int J Antimicrob Agents,2020.doi:10.1016/j.ijantimicag.2020.105955.

[32]Tobaiqy M,Qashqary M,Al-Dahery S,et al.Therapeutic management of COVID-19patients:a systematic review[J].Infect Prevent Pract,2020.doi:https://doi.org/10.1016/ji.nfpip.2020.100061.